283 related articles for article (PubMed ID: 28810886)
1. Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study.
Kim JK; Kim JW; Lee IJ; Joo SM; Lee KH; Cho ES; Yu JS; Jeon TJ; Kim Y; Lee JI; Lee KS
Radiat Oncol; 2017 Aug; 12(1):133. PubMed ID: 28810886
[TBL] [Abstract][Full Text] [Related]
2. Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
Song JE; Jung KS; Kim DY; Song K; Won JY; Lee HW; Kim BK; Kim SU; Park JY; Ahn SH; Seong J; Han KH
Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):396-406. PubMed ID: 28871990
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Significance of ¹⁸F-FDG Uptake in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization or Concurrent Chemoradiotherapy: A Multicenter Retrospective Cohort Study.
Lee JW; Oh JK; Chung YA; Na SJ; Hyun SH; Hong IK; Eo JS; Song BI; Kim TS; Kim DY; Kim SU; Moon DH; Lee JD; Yun M
J Nucl Med; 2016 Apr; 57(4):509-16. PubMed ID: 26742711
[TBL] [Abstract][Full Text] [Related]
4. Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis.
Park MS; Kim SU; Park JY; Kim DY; Ahn SH; Han KH; Chon CY; Seong J
Cancer Chemother Pharmacol; 2013 Jan; 71(1):165-73. PubMed ID: 23079897
[TBL] [Abstract][Full Text] [Related]
5. Early on-treatment predictions of clinical outcomes using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepatocellular carcinoma.
Lee MH; Kim SU; Kim DY; Ahn SH; Choi EH; Lee KH; Lee DY; Seong J; Han KH; Chon CY; Park JY
J Gastroenterol Hepatol; 2012 Feb; 27(2):313-22. PubMed ID: 21793906
[TBL] [Abstract][Full Text] [Related]
6. Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis after Concurrent Chemoradiation Therapy.
Han DH; Joo DJ; Kim MS; Choi GH; Choi JS; Park YN; Seong J; Han KH; Kim SI
Yonsei Med J; 2016 Sep; 57(5):1276-81. PubMed ID: 27401662
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of hepatic arterial infusion chemotherapy in combination with irradiation for advanced hepatocellular carcinoma with portal vein invasion.
Onishi H; Nouso K; Nakamura S; Katsui K; Wada N; Morimoto Y; Miyahara K; Takeuchi Y; Kuwaki K; Yasunaka T; Miyake Y; Shiraha H; Takaki A; Kobayashi Y; Sakaguchi K; Kanazawa S; Yamamoto K
Hepatol Int; 2015 Jan; 9(1):105-12. PubMed ID: 25788384
[TBL] [Abstract][Full Text] [Related]
8. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion.
Kim KM; Kim JH; Park IS; Ko GY; Yoon HK; Sung KB; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
J Gastroenterol Hepatol; 2009 May; 24(5):806-14. PubMed ID: 19207681
[TBL] [Abstract][Full Text] [Related]
9. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.
He MK; Le Y; Li QJ; Yu ZS; Li SH; Wei W; Guo RP; Shi M
Chin J Cancer; 2017 Oct; 36(1):83. PubMed ID: 29061175
[TBL] [Abstract][Full Text] [Related]
10. Comparison of surgical resection versus transarterial chemoembolization with additional radiation therapy in patients with hepatocellular carcinoma with portal vein invasion.
Lee D; Lee HC; An J; Shim JH; Kim KM; Lim YS; Chung YH; Lee YS
Clin Mol Hepatol; 2018 Jun; 24(2):144-150. PubMed ID: 29665630
[TBL] [Abstract][Full Text] [Related]
11. Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis.
Hu J; Bao Q; Cao G; Zhu X; Yang R; Ji X; Xu L; Zheng K; Li W; Xing B; Wang X
Cardiovasc Intervent Radiol; 2020 Jul; 43(7):996-1005. PubMed ID: 31974744
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
Hatooka M; Kawaoka T; Aikata H; Morio K; Kobayashi T; Hiramatsu A; Imamura M; Kawakami Y; Murakami E; Waki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K
Anticancer Res; 2016 Jul; 36(7):3523-9. PubMed ID: 27354618
[TBL] [Abstract][Full Text] [Related]
13. A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma.
Kim HY; Kim JD; Bae SH; Park JY; Han KH; Woo HY; Choi JY; Yoon SK; Jang BK; Hwang JS; Kim SG; Kim YS; Seo YS; Yim HJ; Um SH;
Korean J Hepatol; 2010 Dec; 16(4):355-61. PubMed ID: 21415578
[TBL] [Abstract][Full Text] [Related]
14. Early α-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma.
Kim BK; Ahn SH; Seong JS; Park JY; Kim DY; Kim JK; Lee DY; Lee KH; Han KH
Liver Int; 2011 Mar; 31(3):369-76. PubMed ID: 21083802
[TBL] [Abstract][Full Text] [Related]
15. Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis.
Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Zhu LZ; Xu HF; Yang RJ
Biomed Res Int; 2021; 2021():6670367. PubMed ID: 34337041
[TBL] [Abstract][Full Text] [Related]
16. Chemoembolization alone vs combined chemoembolization and hepatic arterial infusion chemotherapy in inoperable hepatocellular carcinoma patients.
Gao S; Zhang PJ; Guo JH; Chen H; Xu HF; Liu P; Yang RJ; Zhu X
World J Gastroenterol; 2015 Sep; 21(36):10443-52. PubMed ID: 26420971
[TBL] [Abstract][Full Text] [Related]
17. Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma.
Wan X; Zhai X; Yan Z; Yang P; Li J; Wu D; Wang K; Xia Y; Shen F
Oncotarget; 2016 Dec; 7(50):83806-83816. PubMed ID: 27566566
[TBL] [Abstract][Full Text] [Related]
18. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
[TBL] [Abstract][Full Text] [Related]
19. Clinical factors related to recurrence after hepatic arterial concurrent chemoradiotherapy for advanced but liver-confined hepatocellular carcinoma.
Cha H; Yoon HI; Lee IJ; Koom WS; Han KH; Seong J
J Radiat Res; 2013 Nov; 54(6):1069-77. PubMed ID: 23633620
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
Aktas G; Kus T; Emin Kalender M; Kervancioglu S; Sevinc A; Kul S; Camci C
J BUON; 2017; 22(1):150-156. PubMed ID: 28365948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
